CTI BioPharma (CTIC) Announces Continuation without Modification of PAC203 Phase 2 Study of Pacritinib Following IDMC Review

July 2, 2018 7:02 AM

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that following a planned interim data review by the Independent Data Monitoring Committee ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found